CHAPTER 1. Industry Overview of Antifungal Drugs Market
1.1. Definition and Scope
1.1.1. Definition of Antifungal Drugs
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Antifungal Drugs Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Antifungal Drugs Market By Drug Class
1.2.3. Antifungal Drugs Market By Indication
1.2.4. Antifungal Drugs Market By Dosage Form
1.2.5. Antifungal Drugs Market By Distribution Channel
1.2.6. Antifungal Drugs Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Antifungal Drugs Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Antifungal Drugs Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2022
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Antifungal Drugs Market By Drug Class
4.1. Introduction
4.2. Antifungal Drugs Revenue By Drug Class
4.2.1. Antifungal Drugs Revenue (USD Billion) and Forecast, By Drug Class, 2020-2032
4.2.2. Azoles
4.2.2.1. Azoles Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
4.2.3. Echinocandins
4.2.3.1. Echinocandins Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
4.2.4. Polyenes
4.2.4.1. Polyenes Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
4.2.5. Allylamines
4.2.5.1. Allylamines Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
4.2.6. Others
4.2.6.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 5. Antifungal Drugs Market By Indication
5.1. Introduction
5.2. Antifungal Drugs Revenue By Indication
5.2.1. Antifungal Drugs Revenue (USD Billion) and Forecast, By Indication, 2020-2032
5.2.2. Dermatophytosis
5.2.2.1. Dermatophytosis Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. Aspergillosis
5.2.3.1. Aspergillosis Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.4. Candidiasis
5.2.4.1. Candidiasis Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.5. Others
5.2.5.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Antifungal Drugs Market By Dosage Form
6.1. Introduction
6.2. Antifungal Drugs Revenue By Dosage Form
6.2.1. Antifungal Drugs Revenue (USD Billion) and Forecast, By Dosage Form, 2020-2032
6.2.2. Oral Drugs
6.2.2.1. Oral Drugs Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. Ointments
6.2.3.1. Ointments Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4. Powders
6.2.4.1. Powders Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.5. Others
6.2.5.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. Antifungal Drugs Market By Distribution Channel
7.1. Introduction
7.2. Antifungal Drugs Revenue By Distribution Channel
7.2.1. Antifungal Drugs Revenue (USD Billion) and Forecast, By Distribution Channel, 2020-2032
7.2.2. Hospital Pharmacies
7.2.2.1. Hospital Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.3. Retails Pharmacies
7.2.3.1. Retails Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.4. Others
7.2.4.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 8. North America Antifungal Drugs Market By Country
8.1. North America Antifungal Drugs Market Overview
8.2. U.S.
8.2.1. U.S. Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.2.2. U.S. Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
8.2.3. U.S. Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
8.2.4. U.S. Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
8.3. Canada
8.3.1. Canada Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.3.2. Canada Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
8.3.3. Canada Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
8.3.4. Canada Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
8.4. North America PEST Analysis
CHAPTER 9. Europe Antifungal Drugs Market By Country
9.1. Europe Antifungal Drugs Market Overview
9.2. U.K.
9.2.1. U.K. Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.2.2. U.K. Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
9.2.3. U.K. Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
9.2.4. U.K. Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.3. Germany
9.3.1. Germany Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.3.2. Germany Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
9.3.3. Germany Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
9.3.4. Germany Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.4. France
9.4.1. France Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.4.2. France Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
9.4.3. France Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
9.4.4. France Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.5. Spain
9.5.1. Spain Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.5.2. Spain Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
9.5.3. Spain Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
9.5.4. Spain Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.6. Rest of Europe
9.6.1. Rest of Europe Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.6.2. Rest of Europe Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
9.6.3. Rest of Europe Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
9.6.4. Rest of Europe Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Antifungal Drugs Market By Country
10.1. Asia Pacific Antifungal Drugs Market Overview
10.2. China
10.2.1. China Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.2.2. China Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.2.3. China Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
10.2.4. China Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.3. Japan
10.3.1. Japan Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.3.2. Japan Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.3.3. Japan Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
10.3.4. Japan Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.4. India
10.4.1. India Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.4.2. India Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.4.3. India Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
10.4.4. India Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.5. Australia
10.5.1. Australia Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.5.2. Australia Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.5.3. Australia Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
10.5.4. Australia Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.6. South Korea
10.6.1. South Korea Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.6.2. South Korea Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.6.3. South Korea Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
10.6.4. South Korea Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.7.2. Rest of Asia-Pacific Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.7.3. Rest of Asia-Pacific Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
10.7.4. Rest of Asia-Pacific Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Antifungal Drugs Market By Country
11.1. Latin America Antifungal Drugs Market Overview
11.2. Brazil
11.2.1. Brazil Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.2.2. Brazil Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.2.3. Brazil Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
11.2.4. Brazil Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.3. Mexico
11.3.1. Mexico Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.3.2. Mexico Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.3.3. Mexico Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
11.3.4. Mexico Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.4. Rest of Latin America
11.4.1. Rest of Latin America Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.4.2. Rest of Latin America Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.4.3. Rest of Latin America Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
11.4.4. Rest of Latin America Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Antifungal Drugs Market By Country
12.1. Middle East & Africa Antifungal Drugs Market Overview
12.2. GCC
12.2.1. GCC Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.2.2. GCC Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
12.2.3. GCC Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
12.2.4. GCC Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.3. South Africa
12.3.1. South Africa Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.3.2. South Africa Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
12.3.3. South Africa Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
12.3.4. South Africa Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Antifungal Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.4.2. Rest of Middle East & Africa Antifungal Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
12.4.3. Rest of Middle East & Africa Antifungal Drugs Revenue (USD Billion) and Forecast By Dosage Form, 2020-2032
12.4.4. Rest of Middle East & Africa Antifungal Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Antifungal Drugs Market
13.1. Antifungal Drugs Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Antifungal Drugs Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. Company Profile
14.1. Abbott
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (USD Billion), 2022
14.1.3.2. Abbott 2022 Antifungal Drugs Business Regional Distribution
14.1.4. Product /Service and Specification
14.1.5. Recent Developments & Business Strategy
14.2. Astellas Pharma, Inc.
14.3. Bayer AG
14.4. Enzon Pharmaceuticals, Inc.
14.5. Gilead Sciences Inc.
14.6. GlaxoSmithKline plc
14.7. Glenmark
14.8. Johnson & Johnson
14.9. Merck & Co., Inc.
14.10. MerzPharma
14.11. Novartis AG
14.12. Pfizer, Inc.
14.13. Sanofi
The market size of antifungal drugs was USD 14.8 billion in 2022.
The CAGR of antifungal drugs is 3.5% during the analysis period of 2023 to 2032.
The key players operating in the global market are including Abbott, Astellas Pharma, Inc., Bayer AG, Enzon Pharmaceuticals, Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Glenmark, Johnson & Johnson, Merck & Co., Inc., MerzPharma, Novartis AG, Pfizer, Inc., and Sanofi.
North America held the dominating position in antifungal drugs industry during the analysis period of 2023 to 2032.
Asia-Pacific region exhibited fastest growing CAGR for market of antifungal drugs during the analysis period of 2023 to 2032.
The current trends and dynamics in the antifungal drugs industry include increasing incidence of fungal infections, technological advancements in drug development, growing awareness and diagnosis of fungal infections, and rising demand for broad-spectrum antifungal drugs.
The azoles drug class held the maximum share of the antifungal drugs industry.
Customer Satisfaction
Availability - we are always there when you need us
Fortune 50 Companies trust Acumen Research and Consulting
of our reports are exclusive and first in the industry
more data and analysis
reports published till date